Publication:
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy

Simple item page
dc.contributor.authorZeruesenay Destaen_US
dc.contributor.authorRoseann S. Gammalen_US
dc.contributor.authorLi Gongen_US
dc.contributor.authorMichelle Whirl-Carrilloen_US
dc.contributor.authorAditya H. Gauren_US
dc.contributor.authorChonlaphat Sukasemen_US
dc.contributor.authorJennifer Hockingsen_US
dc.contributor.authorAlan Myersen_US
dc.contributor.authorMarelize Swarten_US
dc.contributor.authorRachel F. Tyndaleen_US
dc.contributor.authorCollen Masimirembwaen_US
dc.contributor.authorOtito F. Iwuchukwuen_US
dc.contributor.authorSanika Chirwaen_US
dc.contributor.authorJeffrey Lennoxen_US
dc.contributor.authorAndrea Gaedigken_US
dc.contributor.authorTeri E. Kleinen_US
dc.contributor.authorDavid W. Haasen_US
dc.contributor.otherFairleigh Dickinson Universityen_US
dc.contributor.otherUniversity of Texas Health Science Center at Houstonen_US
dc.contributor.otherMeharry Medical Collegeen_US
dc.contributor.otherIndiana University School of Medicine Indianapolisen_US
dc.contributor.otherCleveland Clinic Foundationen_US
dc.contributor.otherSt. Jude Children's Research Hospitalen_US
dc.contributor.otherUniversity of Torontoen_US
dc.contributor.otherFaculty of Medicine, Ramathibodi Hospital, Mahidol Universityen_US
dc.contributor.otherMassachusetts College of Pharmacy and Health Sciencesen_US
dc.contributor.otherStanford Universityen_US
dc.contributor.otherVanderbilt University School of Medicineen_US
dc.contributor.otherEmory University School of Medicineen_US
dc.contributor.otherDivision of Clinical Pharmacologyen_US
dc.contributor.otherWilkins Hospitalen_US
dc.date.accessioned2020-01-27T09:29:39Z
dc.date.available2020-01-27T09:29:39Z
dc.date.issued2019-10-01en_US
dc.description.abstract© 2019 The Authors Clinical Pharmacology & Therapeutics  © 2019 American Society for Clinical Pharmacology and Therapeutics The HIV type-1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.en_US
dc.identifier.citationClinical Pharmacology and Therapeutics. Vol.106, No.4 (2019), 726-733en_US
dc.identifier.doi10.1002/cpt.1477en_US
dc.identifier.issn15326535en_US
dc.identifier.issn00099236en_US
dc.identifier.other2-s2.0-85068533591en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/51406
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85068533591&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapyen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85068533591&origin=inwarden_US

Files

Collections

Scopus 2019